In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Liraglutide | Synthetic analog Tirzepatide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 4,766 | 2,165 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 805 (793 in people) | 462 (462 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 469 · 30 active49 more mention it but do not test it | 254 · 162 active47 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Liraglutide | Tirzepatide |
|---|---|---|
| Glycemic controlNervous system and cognition | 1,1171067491 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
The FDA label for Mounjaro says: “Adjunct to diet and exercise for glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events”
| Body weightMusculoskeletal | 83481717 | 521501182 |
|---|
| Adverse eventsWhole body | 50449311 | 213213 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 185185 | 179179 |
|---|
| Cardiovascular eventsCardiovascular | 13313111 | 1551523 |
|---|
| Heart functionCardiovascular | 214198142 | 49427 |
|---|
| LipidsMetabolic and weight | 14313733 | 79763 |
|---|
| Liver fat and liver functionMetabolic and weight | 1361279 | 5353 |
|---|
| Blood pressureCardiovascular | 1201182 | 5151 |
|---|
| Inflammation markersRespiratory | 117100152 | 41347 |
|---|
| Kidney functionWhole body | 1049932 | 40391 |
|---|
| Appetite and food intakeNervous system and cognition | 1129517 | 20191 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
Tirzepatide differs from Gastric inhibitory polypeptide (GIP) at 11 positions and in 1 end segment.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 254 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Eli Lilly and Company13,299 participants29 May 2020 to 12 Jun 2025
Type 2 Diabetes Mellitus
Eli Lilly and Company2,539 participants4 Dec 2019 to 6 Jul 2024
Overweight · Obesity
Eli Lilly and Company2,002 participants20 Nov 2018 to 22 Apr 2021
Type 2 Diabetes Mellitus
47 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Liraglutide | Tirzepatide |
|---|---|---|
| Body weightMetabolic and weightCompared as: difference from placebo, in % | −8.03% mean difference Dose studied: 3.0 mg once daily24 weeksn = 572023 | −19.4% Difference Dose studied: maximum tolerated dose (10 or 15 mg)52 weeksn = 6702024 |
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in % | −1.09% HbA1c difference Dose studied: 1.8 mg once daily26 weeksn = 3442009 | −0.4% |
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in ml | −11.5 mL Cardiac adipose tissue change Placebo: −0.01 mL Dose studied: 1.8 mg/d26 weeksn = 512021 | −45 mL Paracardiac adipose tissue change Dose studied: 2.5 mg weekly, increasing to a maximum of 15 mg weekly52 weeks |
| Blood pressureCardiovascularCompared as: difference from placebo, in mm hg | 4 mm Hg Diastolic nocturnal blood pressure difference Dose studied: 1.8 mg once daily24 weeksn = 1002017 | −4.2 mm Hg Net diastolic blood pressure reduction · Shown as a change. The study reports a net diastolic blood pressure reduction of this size. 72 weeks |
| Kidney functionKidney and urinaryCompared as: value in the arm that got the peptide, in % | −40.2% UACR change Dose studied: 1.2-1.8 mg/d26 weeks (after 6 weeks of titration)n = 392019 | −19.3% UACR percent change |
| SleepSleepCompared as: value in the arm that got the peptide, in events/h | −12 events/h Mean difference in AHI 24 weeksn not reported2024 | −34.1 to −27.7 events/h AHI change Dose studied: 10 mg or 15 mg (maximum tolerated dose) |
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 35.7% GI adverse events Placebo: 17.5% Dose studied: 1.8 mg once daily26 weeksn = 2792016 | 42.5% GI adverse events |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 1% Severe hypoglycemia 5.0 years (mean follow-up)n = 5,0472022 | 0.6% Hypoglycemia · tirzepatide 5 mg |
−8.03%
mean difference
Dose studied: 3.0 mg once daily24 weeksn = 572023
−19.4%
Difference
Dose studied: maximum tolerated dose (10 or 15 mg)52 weeksn = 6702024
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Liraglutide | Tirzepatide |
|---|---|---|
| Cardiovascular eventsCardiovascularCompared as: value in the arm that got the peptide, in % | No comparable result 74 randomized-trial results measure it in another way or another unit. | 23.7% event rate Dose studied: up to 15 mg weeklymedian 46.9 monthsn = 13,165 |
HbA1c mean difference
Dose studied: 2.5 mg for 4 weeks, 5.0 mg for 8 weeks12 weeksn not reported2026
Dose studied: 5 mgweek 40/42n not reported2025
Dose studied: up to 15 mg weeklymedian 46.9 monthsn = 13,1652026
Dose studied: 5 mg once weekly40 weeksn not reported2021
−1.09%
HbA1c difference
Dose studied: 1.8 mg once daily26 weeksn = 3442009
−0.4%
HbA1c mean difference
Dose studied: 2.5 mg for 4 weeks, 5.0 mg for 8 weeks12 weeksn not reported2026
−11.5 mL
Cardiac adipose tissue change
Placebo: −0.01 mL
Dose studied: 1.8 mg/d26 weeksn = 512021
−45 mL
Paracardiac adipose tissue change
Dose studied: 2.5 mg weekly, increasing to a maximum of 15 mg weekly52 weeksn = 1062025
4 mm Hg
Diastolic nocturnal blood pressure difference
Dose studied: 1.8 mg once daily24 weeksn = 1002017
−4.2 mm Hg
Net diastolic blood pressure reduction · Shown as a change. The study reports a net diastolic blood pressure reduction of this size.
72 weeksn not reported2024
−40.2%
UACR change
Dose studied: 1.2-1.8 mg/d26 weeks (after 6 weeks of titration)n = 392019
−19.3%
UACR percent change · tirzepatide 5 mg
Dose studied: 5 mgweek 40/42n not reported2025
−12 events/h
Mean difference in AHI
24 weeksn not reported2024
−34.1 to −27.7 events/h
AHI change
Dose studied: 10 mg or 15 mg (maximum tolerated dose)52 weeksn not reported2026
35.7%
GI adverse events
Placebo: 17.5%
Dose studied: 1.8 mg once daily26 weeksn = 2792016
42.5%
GI adverse events
Dose studied: up to 15 mg weeklymedian 46.9 monthsn = 13,1652026
1%
Severe hypoglycemia
5.0 years (mean follow-up)n = 5,0472022
0.6%
Hypoglycemia · tirzepatide 5 mg
Dose studied: 5 mg once weekly40 weeksn not reported2021
| Metabolic pathways and metabolomicsMetabolic and weightCompared as: value in the arm that got the peptide, in mg/dl | No comparable result 5 randomized-trial results measure it in another way or another unit. | −0.69 mg/dL SUA change · tirzepatide 5 mg Placebo: −0.18 mg/dL Dose studied: 5 mg72 weeksn = 2,5392026 |
|---|
| Quality of lifeWhole bodyCompared as: difference from placebo, in points | 3.4 points IWQOL-Lite estimated treatment difference Dose studied: 3.0 mg3 yearsn = 2,2102018 | No comparable result 38 randomized-trial results measure it in another way or another unit. |
|---|
| Body compositionMetabolic and weightCompared as: difference from placebo, in % | −0.24% Treatment difference Dose studied: 3.0 mg target dose, once daily40 weeksn = 1282024 | No comparable result 12 randomized-trial results measure it in another way or another unit. |
|---|
No comparable result
74 randomized-trial results measure it in another way or another unit.
23.7%
event rate
Dose studied: up to 15 mg weeklymedian 46.9 monthsn = 13,1652026
No comparable result
5 randomized-trial results measure it in another way or another unit.
−0.69 mg/dL
SUA change · tirzepatide 5 mg
Placebo: −0.18 mg/dL
Dose studied: 5 mg72 weeksn = 2,5392026
3.4 points
IWQOL-Lite estimated treatment difference
Dose studied: 3.0 mg3 yearsn = 2,2102018
No comparable result
38 randomized-trial results measure it in another way or another unit.
−0.24%
Treatment difference
Dose studied: 3.0 mg target dose, once daily40 weeksn = 1282024
No comparable result
12 randomized-trial results measure it in another way or another unit.